RSP strengthens our team by adding two industry veterans: scientific and technical expert Michael Gerstenberg, and digital health leader Sune K-Holm Nielsen. Michael and Sune will add fuel to our efforts toward achieving U.S. market approval of our state-of-the-art technology.
During the past year, RSP ran a large clinical study with more than 160 patients. The terrific results, user interaction, and performance of the technology prove RSP is ready for a pivotal study. This validation has contributed to the Company’s success in attracting top caliber talent from the science, advanced technology, and digital health sectors.
Anders Weber, RSP Chief Executive Officer, said: “We are proud of the performance that we have seen in our recent clinical study, which is an important step forward for the future in diabetes prevention and management. We believe that the ability to measure glucose non-invasively will be a game-changer, and to accelerate our efforts we succeeded in hiring two experienced executive leaders to strengthen our management team. This will strengthen our position as the leading technology provider of non-invasive glucose measuring solutions both for diabetes management as well as for digital health applications”
Sune has more than 10 years of experience in the digital health space. He joins RSP from Kry-Livi, where he held several leadership roles of huge impact to the company, including Director of Global Partnerships, Director of Psychology, and most recently Director of Global New Business. Sune has a strong track record in delivering digital health applications to the fast-growing market. Before his time at KRY, he was Managing Director of another digital health company, MeeDoc.
This latest addition to RSP’s management team follows a recent appointment of Michael Gerstenberg, PhD, as Chief Science Officer. Michael has more than 20 years of leadership experience from the medical device and pharmaceutical industry. He joined RSP from KLIFO, where he served as Project Director and led various medical device projects. Prior to this, he held several positions at Novo Nordisk, including Scientific Director, Corporate Vice President Partner and most recently Research Project Director.
These appointments follow the company’s recent outstanding results and the imminent closure of our Series C round. The company is working to bring a truly non-invasive glucose monitoring device targeting prevention and care of diabetes to the U.S market. In addition to this program, RSP aims to further miniaturize the pipeline of additional non-invasive Touch Glucose Monitoring™ (TGM) devices.
Please see the press release below for additional information: